| Prev Close: | N/A |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 398.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | N/A |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | N/A |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | 0.00 |
|---|
| EPS (ttm): | 0.06 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in .
Headlines
- BTG raises revenue forecastsSharecast(Wed, 3 Oct)
- Barclays: the main players at the bankTelegraph(Sun, 2 Sep)
- BTG PLC - Holding(s) in CompanyAFX CNF(Thu, 9 Aug)
- BTG takes a hit after Astra halts CytoFab developmentSharecast(Wed, 8 Aug)
- BTG PLC - Research UpdateAFX CNF(Wed, 8 Aug)
- London midday: StanChart drags banks lowerSharecast(Tue, 7 Aug)
- London midday: StanChart drags banks lowerSharecast(Tue, 7 Aug)
- London close: Stocks higher despite remarks from German ministerSharecast(Thu, 2 Aug)
- London midday: Footsie shrugs off PMI disappointmentSharecast(Wed, 1 Aug)
- Roger and Diana Jenkins in £150m 'happy' divorceTelegraph(Sun, 29 Jul)
Key Statistics
| Forward P/E (1 yr): | 0.00 |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-13)
: | 13.50 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.2 |
|---|
| PEG Ratio (5 yr expected): | 3.28 |
|---|
Business Summary
BTG plc, a specialist healthcare company, engages in developing and commercializing products targeting critical care, cancer, and other disorders. The company markets and sells specialty pharmaceuticals, including CroFab, a snake bite antivenom to...
View More 
1.77%